Table 1

Characteristics of the patients included or non included in Group 1 and Group 2

Group 1
 Group 2
Characteristic
 Included
N = 170
 Non-included
N = 62
 Significance p
 Included N = 97
 Non-included
N = 69
 Significance p
 Significance p training
vs validation
Demographics
     Age at biopsy, mean (se), years
 52.8 (0.87)
 54.9 (1.47)
 0.18
 48.5 (1.28)
 49.1 (1.45)
 0.18
 0.01
     Male, n (%)
 98 (58)
 39 (63)
57 (59)
 38 (69)
 0.64
 0.86
Metabolic factor (%)
     Diabetes
 61/170 (36)
 10/62 (16)
 0.004
 31/97 (32)
 8/97 (12)
 0.62
 0.001
     Arterial Hypertension
 53/170 (31)
 6/62 (10)
 0.14
 15/97 (16)
 16/97 (23)
 0.21
 0.001
     BMI greater than 27 kg/m2
 85/141 (60)
 12/21 (57)
 0.78
 43/97 (44)
 22/97 (32)
 0.11
 0.42
     Triglycerides greater than 1.5
 68/161 (42)
 17/42 (40)
 0.87
 35/97 (36)
 15/97 (22)
 0.047
 0.33
     HDL cholesterol lower than 40 mg/L
 36/151 (24)
 6/38 (16)
 0.29
 15/94 (16)
 15/66 (23)
 0.28
 0.14
     Metabolic factor






     None
 21/170 (24)
 34/62 (55)
 P < 0.0001

P < 0.0001
     At least one
 134/170 (79)
 28/62 (45)




Alcohol consumption, n (%)
     No
 118/170 (69)
 51/62 (79)
 0.63
 57/97 (59)
 41/69 (59)
 0.63
 0.20
     Yes
 52/170 (31)
 11/62 (21)
40/97 (41)
 28/69 (41)

Fibrosis stage, n (%)
     Non advanced fibrosis
 130/170 (76)
 59/60(98)
 0.001
 66/97(68)
 51/69(74)
 0.48
 0.13
          No fibrosis (F0)
 77/170 (45)
 39/60 (65)
26/97 (27)
 21/69 (30)

          Perisinusoidal or periportal (F1)
 54/170 (31)
 20/60 (33)
40/97 (41)
 30/69 (43)

               1A: mild, zone 3, perisinusoidal
 29/170 (17)
 19/60 (31)
18/97 (19)
 18/69 (25)

               1B: moderate, zone 3, perisinusoidal
 2/170 (1)
1/60 (2)

0/97 (0)
22/97 (22)
 0/69 (0)
12/69 (18)

               1C: portal/periportal
 22/170 (13)
 0/60 (0)
31/97 (32)
 18/69(26)

          Advanced Fibrosis
 40/170 (24)
 1/60(2)
15/97 (15)
 13/69 (19)

               Perisinusoidal and portal/periportal (F2)
 20/170 (12)
11/170 (7)
 0/60 (0)
0/60 (0)
12/97 (12)
4/97 (4)
 2/69 (3)
3/69 (4)

     Bridging (F3)
 9/170 (5)
 1/60 (2)




     Cirrhosis (F4)






Non alcoholo-steato-hepatitis, n (%)
     No
 75/170 (44)
 25/60 (41)
 0.15
 29/97 (30)
 40/69(58)
 0.001
 0.003
     Borderline (Probable)
 67/170 (39)
 26/60 (44)
35/97 (36)
 19/69 (28)

     Yes
 28/170 (17)
 9/60 (15)
33/97 (34)
 10/69 (14)

Steatosis
Histology
     Absence or <5%
 22/170 (13)
 12/60 (20)
 0.38
 19/97 (20)
 13/69 (19)
 0.38
 0.22
     6–32
 57/170 (34)
 14/60 (23)
22/97 (23)
 27/69 (39)

     33–65
 43/170 (25)
 16/60 (27)
27/97 (28)
 10/69 (14)

     66–100
 48/170 (28)
 18/60 (30)
29/97 (30)
 19/60 (28)

Interval between biopsy and serum,
     median
 0
 -100
 <0.001
 0
 0
 0.90
 0.07
     (95%CI),
 [0; 1]
 [-215; 0]
[0; 0]
 [0; 0]

     Range days
 -87;+89
 -538; +540
-24;+49
 -42; +40

Biopsy quality mean (se)
     Sample size
 20.0 (0.5)
 19.7 (0.9)
 0.68
 17.8 (0.7)
 21.4 (0.9)
 0.001
 0.007
     Number of fragment
 2.3 (0.2)
 2.3 (0.2)
 0.41
 2.3 (0.2)
 2.2 (0.2)
 0.76
 0.52
     Number of portal tracts
 16.3 (0.6)
 16.3 (1.1)
 0.79
 13.6 (0.6)
 17.1 (1.0)
 0.008
 0.01
Serum biochemical markers, mean (se)
     α2-macroglobulin (g/L)
 1.68 (0.05)
 1.78 (0.11)
 0.26
 1.72 (0.06)
 1.76 (0.08)
 0.47
 0.38
     ALT (IU)
 71 (3)
 64 (6)
 0.26
 79 (5)
 84 (10)
 0.64
 0.23
     AST (IU)†
 50 (3)
 42 (3)
 0.10
 45 (3)
 52 (5)
 0.10
 0.009
     Apolipoprotein A1(g/L)
 1.47 (0.03)
 1.46 (0.07)
 0.84
 1.59 (0.07)
 1.53 (0.04)
 0.80
 0.07
     GGT (IU/L)
 110 (11)
 113 (19)
 0.96
 132 (12)
 158 (19)
 0.96
 0.03
     Haptoglobin (g/L)
 1.10 (0.04)
 1.19 (0.15)
 0.69
 1.12 (0.10)
 1.02 (0.05)
 0.16
 0.28
     Total bilirubin (μmol/L)
 14.5 (3.1)
 12.8 (2.0)
 0.43
 12.6 (0.6)
 13.6 (1.0)
 0.89
 0.64
     FibroTest (0.00–1.00)
 0.30 (0.02)
 0.37 (0.05)
 0.18
 0.29 (0.02)
 0.33 (0.02)
 0.21
 0.84
     ActiTest (0.00–1.00)
 0.39 (0.02)
 0.34 (0.04)
 0.24
 0.41 (0.02)
 0.43 (0.03)
 0.55
 0.26

Ratziu et al. BMC Gastroenterology 2006 6:6   doi:10.1186/1471-230X-6-6